Dale McElveen is an accomplished clinical operations leader with 25+ years of experience in global clinical trials, contributing to multiple drug approvals by the FDA and other health authorities across Canada, Europe, Japan, and China.
Her career began as a Clinical Research Associate (CRA), progressing through increasing levels of responsibility across four pharmaceutical and biotech companies. Most recently, she served as Director of Global Clinical Development Operations, working remotely from the Baltimore-Washington metro area. In this role, Dale oversaw the recruitment, training, and professional development of Clinical Study Managers (CSMs) responsible for managing global clinical trials.
A dedicated advocate for diversity in clinical trials, Dale actively contributes to industry initiatives focused on health equity. She is a former board member and Director of Membership for Women of Color in Pharma (WOCIP) and remains an active member of both WOCIP and the Healthcare Businesswomen’s Association (HBA). She is also a graduate of the Tigerlily ANGEL Advocacy Program with the Tigerlily Foundation. She frequently engages in industry conferences to remain at the forefront of the evolving healthcare and pharmaceutical landscape.
Dale’s passion for health equity and inclusive clinical research is deeply personal, shaped by her experiences as a breast cancer survivor and the health disparities highlighted during the COVID-19 pandemic. She welcomes the opportunity to leverage this passion and her professional expertise to promote accelerated drug development and improve health outcomes for all. Dale believes that this is indeed possible with better collaboration with patients/caregivers, their communities, healthcare organizations, advocacy organizations, regulators, vendors, HCPs and other partners within the healthcare/research ecosystem.